AVEO Oncology announced that NASDAQ halted trading of AVEO common stock this morning, May 2, 2013. The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee meets today to discuss the New Drug Application for tivozanib for the treatment of patients with advanced renal cell carcinoma. According to the timelines established by the Prescription Drug User Fee Act, the review of the NDA is expected to be complete by July 28, 2013.
- Health Care Industry
- New Drug Application